Browse CXXC1

Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus speckle Note=Associated with euchromatin. During mitosis, excluded from condensed chromosomes.
Domain PF00628 PHD-finger
PF12269 CpG binding protein zinc finger C terminal domain
PF02008 CXXC zinc finger domain
Function

Transcriptional activator that exhibits a unique DNA binding specificity for CpG unmethylated motifs with a preference for CpGG.

> Gene Ontology
 
Biological Process GO:0006479 protein methylation
GO:0006986 response to unfolded protein
GO:0008213 protein alkylation
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018205 peptidyl-lysine modification
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0032259 methylation
GO:0034620 cellular response to unfolded protein
GO:0034968 histone lysine methylation
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036498 IRE1-mediated unfolded protein response
GO:0043414 macromolecule methylation
GO:0051568 histone H3-K4 methylation
Molecular Function GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001159 core promoter proximal region DNA binding
GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016278 lysine N-methyltransferase activity
GO:0016279 protein-lysine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0018024 histone-lysine N-methyltransferase activity
GO:0042054 histone methyltransferase activity
GO:0042800 histone methyltransferase activity (H3-K4 specific)
GO:0045322 unmethylated CpG binding
Cellular Component GO:0016363 nuclear matrix
GO:0016604 nuclear body
GO:0016607 nuclear speck
GO:0034399 nuclear periphery
GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
GO:0048188 Set1C/COMPASS complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-381070: IRE1alpha activates chaperones
R-HSA-392499: Metabolism of proteins
R-HSA-381119: Unfolded Protein Response (UPR)
R-HSA-381038: XBP1(S) activates chaperone genes
Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXXC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXXC1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.5 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXXC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0650.715
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0320.987
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0920.949
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.270.377
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4760.823
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0110.997
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3190.312
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4430.744
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1510.923
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3590.828
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3890.874
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2480.00476
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXXC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXXC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXXC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXXC1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXXC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXXC1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXXC1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXXC1
NameCXXC finger protein 1
Aliases HsT2645; PCCX1; hCGBP; PHF18; CGBP; ZCGPC1; CpG binding protein; DNA-binding protein with PHD finger and CXX ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXXC1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.